middle.news
Nyrada Advances Phase I Trial of NYR-BI03 with No Safety Concerns
3:32am on Monday 2nd of June, 2025 AEST
•
Biotechnology
Read Story
Nyrada Advances Phase I Trial of NYR-BI03 with No Safety Concerns
3:32am on Monday 2nd of June, 2025 AEST
Key Points
Phase I trial progresses to third cohort after positive safety and pharmacokinetic review
NYR-BI03 targets TRPC ion channels with dual neuro- and cardioprotective potential
Preclinical studies show significant brain and heart tissue protection
Final Phase I results expected in Q3 2025
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
NYRADA (ASX:NYR)
OPEN ARTICLE